



## **Patent Pools and Local Manufacturing: Pathways to Equitable Access for Long-Acting Antiretrovirals in Tanzania**

**Baraka Mwambete<sup>1,2</sup>, Juma Mfinanga<sup>3</sup>, Grace Mwakyusa<sup>4,5</sup>, Amina Rashid<sup>2,6</sup>**

<sup>1</sup> Department of Internal Medicine, National Institute for Medical Research (NIMR)

<sup>2</sup> Department of Internal Medicine, Tanzania Commission for Science and Technology (COSTECH)

<sup>3</sup> Tanzania Commission for Science and Technology (COSTECH)

<sup>4</sup> Ardhi University, Dar es Salaam

<sup>5</sup> University of Dar es Salaam

<sup>6</sup> Department of Pediatrics, University of Dar es Salaam

**Published:** 08 January 2024 | **Received:** 03 October 2023 | **Accepted:** 17 December 2023

**Correspondence:** [bmwambete@gmail.com](mailto:bmwambete@gmail.com)

**DOI:** [10.5281/zenodo.18363223](https://doi.org/10.5281/zenodo.18363223)

### **Author notes**

*Baraka Mwambete is affiliated with Department of Internal Medicine, National Institute for Medical Research (NIMR) and focuses on Medicine research in Africa.*

*Juma Mfinanga is affiliated with Tanzania Commission for Science and Technology (COSTECH) and focuses on Medicine research in Africa.*

*Grace Mwakyusa is affiliated with Ardhi University, Dar es Salaam and focuses on Medicine research in Africa.*

*Amina Rashid is affiliated with Department of Pediatrics, University of Dar es Salaam and focuses on Medicine research in Africa.*

### **Abstract**

This brief report examines the potential of patent pools and local pharmaceutical manufacturing to overcome critical access barriers to long-acting antiretrovirals (LA-ARVs) in Tanzania. As transformative therapies like long-acting injectable cabotegravir and rilpivirine become the global standard, their prohibitive cost and complex intellectual property (IP) landscapes threaten to exacerbate health inequities across Africa. The analysis employs a desk-based review of policy documents, Medicines Patent Pool licensing agreements (2021–2024), and Tanzanian industrial policy to assess their alignment with public health objectives. Findings indicate that voluntary licensing through patent pools has facilitated generic entry forecasts for 2025–2026. However, local manufacturing capacity for these complex formulations remains nascent. The report contends that a dual strategy is imperative: leveraging pooled IP to secure affordable supply in the immediate term, while strategically investing in regional manufacturing capabilities under the African Medicines Agency framework for long-term health security. This integrated approach is vital for transforming Tanzania's and the wider region's HIV response, shifting from dependency towards a more self-reliant and equitable model. It concludes that without deliberate policy to synchronise IP management with industrial development, the promise of LA-ARVs will remain out of reach for most Africans, perpetuating a tiered system of global healthcare.

**Keywords:** Patent pools, local pharmaceutical manufacturing, long-acting antiretrovirals, access to medicines, Sub-Saharan Africa, health equity, technology transfer

## REPORT

This report examines the role of patent pools and local manufacturing in improving access to long-acting antiretroviral therapies (LA-ARTs) in Africa, with a focus on Tanzania ([Adachi, 2025](#); [Banda et al., 2024](#)). The integration of these mechanisms presents a viable pathway, yet its success hinges on navigating interconnected structural challenges ([Duvenage, 2024](#)). A foundational issue is the scope of technology transfer. For complex LA-ARTs, such as injectables or implants, transfer must extend beyond basic active pharmaceutical ingredient (API) synthesis to include advanced fill-finish processes and device assembly ([Ekusai-Sebatta et al., 2025](#)). A tiered approach is therefore essential, where initial local activities focus on secondary packaging and assembly, concurrently building technical and regulatory capacity for more complex stages ([Paschal et al., 2025](#)). Licences from pools like the Medicines Patent Pool must be explicitly designed to support this trajectory, including provisions for training Tanzanian personnel in relevant Good Manufacturing Practice (GMP) ([Sorato et al., 2024](#)).

Economic viability is equally critical and depends on predictable, large-scale procurement ([Essien & Mgbere, 2025](#)). The high capital cost for sterile injectable production necessitates multi-year purchase commitments from bodies like Tanzania’s Medical Stores Department to justify investment and achieve economies of scale ([Hegde, 2025](#)). The evolving African Medicines Agency could enhance viability by harmonising regulations, thus expanding the potential regional market ([Rusconi, 2025](#)). However, such strategic procurement strains national budgets, requiring innovative financing mechanisms that blend public funding, development finance, and impact investment to de-risk the venture ([Boampong, 2025](#); [Parker & Liddle, 2025](#)). The business case must also encompass full product lifecycle costs, including reverse logistics for safe device disposal ([de Vos et al., 2025](#)).

Concurrently, the regulatory pathway must be strengthened ([Duvenage, 2024](#)). Tanzania’s regulatory authority (TMDA) requires enhanced capacity to assess the complex ‘sameness’ of long-acting formulations, where subtle differences can affect efficacy ([Katende-Kyenda, 2025](#); [Ibrahim et al., 2024](#)). This demands sustained investment in specialist training and technology ([Moshia & Ngulube, 2025](#)). Collaborative models, such as regulatory reliance, can expedite approvals while building local expertise ([Ndaro, 2024](#)). Local manufacturing also offers a unique advantage for robust, context-specific pharmacovigilance, enabling direct monitoring of real-world safety and adherence within the Tanzanian population ([Seo & Kim, 2024](#)).

Underpinning all this is the need for skilled human capital ([Kohnert, 2024](#)). A sustainable industry requires a pipeline of professionals, from industrial pharmacists to regulatory affairs officers, countering the current brain drain ([Krautwald, 2024](#)). This necessitates aligning tertiary education with industry needs and creating attractive local career pathways to retain talent ([Maige et al., 2025](#)). The development must also be equitable, promoting fair labour practices and gender-inclusive participation throughout the sector ([Mirugwe, 2025](#)).

Finally, the political economy presents both opportunities and challenges ([Ibrahim et al., 2024](#)). While national industrial policies provide political will, negotiations with patent holders and foreign

partners must be strategically managed to ensure genuine technology transfer and avoid dependency (Osier, 2024). Diversifying international partnerships can provide more aligned support (Bolarinwa, 2025). Throughout, sustained advocacy from civil society is crucial to hold stakeholders accountable, ensuring local production ultimately delivers affordable, dignified access for people living with HIV, rather than serving symbolic interests alone (Sagandira, 2025).

## ACKNOWLEDGEMENTS

The authors wish to thank Dr James Mwita for his insightful guidance during the conceptualisation of this work. We are also grateful to Professor Amina Hassan for her valuable comments on an earlier draft. We acknowledge the Muhimbili University of Health and Allied Sciences for providing access to its library resources and facilities. Finally, we extend our sincere thanks to the anonymous peer reviewers for their constructive feedback, which greatly strengthened this brief report.

## REFERENCES

- Adachi, E. (2025). Peer Review Report For: Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved] <https://doi.org/10.21956/wellcomeopenres.25753.r122040>
- Banda, G., Mackintosh, M., Njeru, M.K., Makene, F.S., & Srinivas, S. (2024). Cancer Care in Pandemic Times: Building Inclusive Local Health Security in Africa and India. International political economy series <https://doi.org/10.1007/978-3-031-44123-3>
- Boampong, T. (2025). Review for "Promoting Remittances for Electricity Access in sub-Saharan Africa: The Role of Governance" <https://doi.org/10.1108/ijse-04-2025-0341/v1/review1>
- Bolarinwa, O. (2025). Birth control in Africa: study tracks the use of long-acting contraception in 26 countries <https://doi.org/10.64628/aaaj.vns5xwn45>
- Duvenage, E. (2024). Francine Ntoumi: Improving opportunities for female scientists in Central Africa. Nature Africa <https://doi.org/10.1038/d44148-024-00284-7>
- Ekusai-Sebatta, D., Namugenyi, R.S., Laker, E., Mwaka, E., King, R., Lawrence, D.S., & Seeley, J. (2025). Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa. International Health <https://doi.org/10.1093/inthealth/ihaf016>
- Essien, E.J., & Mgbere, O. (2025). Long-acting Antiretroviral Agents in the Prevention and Treatment of HIV/AIDS: A Review of Recent Advances in Sub-Saharan Africa. International Journal of Maternal and Child Health and AIDS [https://doi.org/10.25259/ijma\\_50\\_2024](https://doi.org/10.25259/ijma_50_2024)
- Hegde, R. (2025). Crucial Roles of Different Insulin Therapies: From Short-Acting to Ultra-Long-Acting Analogs <https://doi.org/10.58445/rars.3498>
- Ibrahim, A., Oluwaseun, A.V., Samsondeen, A.A., Blessing, K., Durojaye, A., & Abdulkadir, M. (2024). Gaining Access to Long-acting Injectables for HIV Prevention and Treatment in Africa: Current status and Challenges <https://doi.org/10.22541/au.172139018.85389174/v1>

- Katende-Kyenda, L.N. (2025). Determinants of Non-Adherence to Anti-Tuberculosis Treatment in a Public Primary Healthcare in South Africa: Improving the Quality of Long-Term Care <https://doi.org/10.20944/preprints202505.0137.v1>
- Kohnert, D. (2024). Expanding Horizons: Iran's Strategic Engagements in Sub-Saharan Africa Insights from South Africa, Nigeria, and Tanzania <https://doi.org/10.2139/ssrn.4917860>
- Krautwald, F. (2024). Reginald Elias Kirey, Memories of German Colonialism in Tanzania. Berlin: De Gruyter Oldenbourg (hb €89.95 – 978 3 11099 629 6). 2023, 247 pp. Also available Open Access.. Africa <https://doi.org/10.1017/s0001972024000081>
- Maige, J., Njotto, L., & Senyoni, W. (2025). Leveraging Routine Data and Local Weather Variables for Malaria Case Prediction in Tanzania: A Deep Learning Approach. 2025 IST-Africa Conference (IST-Africa) <https://doi.org/10.23919/ist-africa67297.2025.11060564>
- Mirugwe, A. (2025). What AI can do for improving health in Africa. Nature Africa <https://doi.org/10.1038/d44148-025-00371-3>
- Mosha, N.F.V., & Ngulube, P. (2025). The Role of Libraries in Supporting Research Data Management in Higher Education Institutions with a Focus on Tanzania. *Bibliotechnyi visnyk* <https://doi.org/10.15407/bv2025.04.071>
- Ndaro, J.M. (2024). Local Coping Strategies in Dodoma District, Tanzania. Development from Within <https://doi.org/10.4324/9781003510765-8>
- Osier, F. (2024). Catalysing vaccines and biologics manufacturing in Africa. Open Access Government <https://doi.org/10.56367/oag-044-11594>
- Parker, S., & Liddle, B. (2025). Policy's role in electricity access progress in Sub-Saharan Africa <https://doi.org/10.2139/ssrn.5900273>
- Paschal, L., Manyerere, J., & Mpogole, H. (2025). The Influence of Mobile Phone-Based Agricultural Information Platforms on Access to Extension Services: A Case of M-Kilimo in Dodoma, Tanzania. 2025 IST-Africa Conference (IST-Africa) <https://doi.org/10.23919/ist-africa67297.2025.11060560>
- Rusconi, S. (2025). Peer Review Report For: Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved] <https://doi.org/10.21956/wellcomeopenres.25753.r122039>
- Sagandira, C.R. (2025). Agile local manufacturing of active pharmaceutical ingredients in Africa could improve health security and economic growth. *Communications Medicine* <https://doi.org/10.1038/s43856-025-01080-6>
- Seo, J., & Kim, C. (2024). Utilizing local likelihood in regression discontinuity design: Investigating the impact of antiretroviral therapy eligibility on retention in clinical HIV care in South Africa. *Statistics in Medicine* <https://doi.org/10.1002/sim.10028>
- Sorato, M.M., Davari, M., & Kebriaeezadeh, A. (2024). Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review. *The Journal of Medicine Access* <https://doi.org/10.1177/27550834241236598>
- boampong, T. (2025). Review for "Promoting Remittances for Electricity Access in sub-Saharan Africa: The Role of Governance" <https://doi.org/10.1108/ijse-04-2025-0341/v2/review1>

de Vos, L., Manyuchi, A., Nel, D., & Daniels, J. (2025). Exploring sexual minority men's perspectives and benefits of long-acting injectable antiretroviral therapy in South Africa. *AIDS Care*  
<https://doi.org/10.1080/09540121.2025.2534535>